R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentsNovartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company Share XR&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentshttps://pharmaphorum.com/views-and-analysis/rd-roundup-novartis-crispr-opdivo/
EU regulators accept Novartis’ triple asthma comboEuropean regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments Share XEU regulators accept Novartis’ triple asthma combohttps://pharmaphorum.com/news/eu-regulators-accept-novartis-triple-asthma-combo/
Novartis shows off pipeline – including 25 potential blockbustersNovartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company Share XNovartis shows off pipeline – including 25 potential blockbustershttps://pharmaphorum.com/news/novartis-shows-off-pipeline-including-25-potential-blockbusters/
Takeda to sell dry eye drug to Novartis for up to $5.3bnTakeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch Share XTakeda to sell dry eye drug to Novartis for up to $5.3bnhttps://pharmaphorum.com/news/takeda-to-sell-dry-eye-drug-to-novartis-for-up-to-5-3bn/
Collaborating to fight NASHEric Hughes, Global Development Unit head at Novartis for Immunology, Hepatology & Dermatology, believes that collaboration is going Share XCollaborating to fight NASHhttps://pharmaphorum.com/r-d/views-analysis-r-d/collaborating-to-fight-nash/
Sandoz strikes deal with EirGenix for Herceptin biosimilarSandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Share XSandoz strikes deal with EirGenix for Herceptin biosimilarhttps://pharmaphorum.com/news/sandoz-strikes-deal-with-eirgenix-for-herceptin-biosimilar/
Psoriasis and cardio drugs drive Novartis’ Q1 salesNovartis has begun 2019 at a sprint, upgrading its sales forecasts for the year after strong performances from Share XPsoriasis and cardio drugs drive Novartis’ Q1 saleshttps://pharmaphorum.com/news/psoriasis-and-cardio-drugs-drive-novartis-q1-sales/
Second death in gene therapy trial prompts investigationA second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – Share XSecond death in gene therapy trial prompts investigationhttps://pharmaphorum.com/news/second-death-in-novartis-gene-therapy-trial-prompts-investigation/
Novartis files potential blockbuster eye drug with FDANovartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough Share XNovartis files potential blockbuster eye drug with FDAhttps://pharmaphorum.com/news/novartis-files-potential-blockbuster-eye-drug/
